First EB patient in phase 2 cancer study responds very well to treatment
Already one year ago, the first 24-year-old EB patient started the therapy with a potential new cancer drug at the EB-Haus Austria. At that time, the cancer lesions were deemed unresectable and first-in-line treatments did not work. She repeatedly developed several squamous cell carcinomas which threatened her life. Participation in the phase 2 Rigosertib study was a great hope for her in the fight against the progressive cancer.
One year after starting, the patient is doing well. The long and arduous journey of about 800 km once a month for study visits was extraordinarily exhausting, but worth every kilometer.
The new drug is being tested for tolerability, safety and efficacy in the course of a multi-center study on the way to approval. Financial support for the current phase 2 trial was approved through an international EB funding round (AP Call 2015) and it is funded through DEBRA UK. Find more on clinicalTrials.gov.
This study is open for recruitment. In addition, to the study center in Salzburg, there is also a study center in London.
The drug is also being tested at Thomas Jefferson University in the USA, where a second trial for Rigosertib is registered.
